

The effect of pharmacological agents on uterine junctional zone contractions during mock embryo transfer: a randomised double-blind study

Submission date 30/09/2004	Recruitment status No longer recruiting	☐ Prospectively registered
Registration date 30/09/2004	Overall study status Completed	☐ Protocol
Last Edited 31/03/2020	Condition category Pregnancy and Childbirth	☐ Statistical analysis plan
		☐ Results
		☐ Individual participant data
		☐ Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr Frank Biervliet

Contact details

Academic Department of Obstetrics & Gynaecology
Hull & East Yorkshire (NHS) Trust
The Princess Royal Hospital
Salhouse Road
Hull
United Kingdom
HU8 9HE
+44 (0)1482 701151
abc@email.com

Additional identifiers

Protocol serial number

N0084096582

Study information

Scientific Title

The effect of pharmacological agents on uterine junctional zone contractions during mock embryo transfer: a randomised double-blind study

Study objectives

To assess if junctional zone contractions can be reduced by pharmacological agents.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Primary study design

Interventional

Study design

Randomised double-blind study

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Pregnancy and Childbirth: Embryo transfer

Interventions

The patient's baseline junctional zone contractions will be established following a 5 minute scan. Video tapes taken of both the pre and post mock embryo transfer will be assessed by two researchers who will be unaware of treatment.

20 patients allocated to the nitric oxide group, 20 to the non-steroidal anti-inflammatory group, 20 control and 20 to the COX-2 inhibitor group.

Intervention Type

Drug

Phase

Not Applicable

Primary outcome(s)

1. Number of contractions per unit time
2. Speed of contractions in cm/min
3. Type of contractions
4. Speed of Echovist
5. Distance traveled by Echovist

Key secondary outcome(s)

Not provided at time of registration

Completion date

10/12/2003

Eligibility

Key inclusion criteria

Not provided at time of registration

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

Female

Key exclusion criteria

Not provided at time of registration

Date of first enrolment

01/04/2000

Date of final enrolment

10/12/2003

Locations

Countries of recruitment

United Kingdom

England

Study participating centre

The Princess Royal Hospital

Hull

United Kingdom

HU8 9HE

Sponsor information

Organisation

Department of Health

Funder(s)

Funder type

Research organisation

Funder Name

The North and South Bank Research and Development Consortium (UK)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration